Source-grounded facts extracted from ARVINAS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Noah Berkowitz departed as chief medical officer at ARVINAS, INC..
“On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”).”
ARVINAS, INC. reported financial results for first quarter 2026.
“On May 12, 2026, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026 and provided a corporate update.”
ARVINAS, INC. entered into License Agreement with Rigel Pharmaceuticals, Inc. valued at $70.0 million (effective 2026-05-11).
“On May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”).”
Ian Taylor resigned as President of Research and Development at ARVINAS, INC..
“On June 4, 2025, Ian Taylor, Ph.D., President of Research and Development of Arvinas, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company and retire, effective June 6, 2025”
ARVINAS, INC. announced a restructuring with charges of approximately $10 million affecting all areas of the Company (approximately 33%).
“On April 30, 2025, the Company's management, pursuant to authority delegated by the Board of Directors of the Company, committed the Company to and approved a reduction of the Company’s workforce by approximately 33% across all areas of the Company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company’s portfolio. The Company expects the workforce reduction will be substantially completed by the end of the second quarter of 2025. The Company expects that it will incur approximately $10 million in costs in connection with the workforce reduction, which consist of severance and other one-time employee termination benefit expenses, which the Company expects to recognize primarily in the second quarter of 2025.”
Angela Cacace was appointed as Chief Scientific Officer at ARVINAS, INC..
“and the appointment of Angela Cacace, Ph.D. as the Company’s chief scientific officer (“CSO”), a role previously held by Dr. Taylor.”
Ian Taylor was appointed as President of Research and Development at ARVINAS, INC..
“On June 17, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Ian Taylor, Ph.D. as the Company’s president of research and development (“R&D”), a role previously held by John Houston, Ph.D.,”
ARVINAS, INC. reported financial results for the first quarter ended March 31, 2024.
“On May 7, 2024 , Arvinas, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update.”
ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).
“On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).”
Ron Peck departed as chief medical officer at ARVINAS, INC..
“On March 14, 2024, the Company notified Ron Peck, M.D., the Company’s previously serving chief medical officer, of Dr. Berkowitz’s pending appointment and the reassignment of the responsibilities of chief medical officer to Dr. Berkowitz effective as of March 18, 2024.”
Noah Berkowitz was appointed as chief medical officer at ARVINAS, INC..
“On March 18, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer, effective as of March 18, 2024.”
ARVINAS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 27, 2024 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.”
Randy Teel was appointed as interim Chief Financial Officer, Treasurer and principal financial officer at ARVINAS, INC..
“On February 19, 2024, the Board of Directors of the Company appointed Randy Teel, Ph.D., the Company’s current Senior Vice President, Corporate and Business Development, to serve as the Company’s interim Chief Financial Officer, Treasurer and principal financial officer, effective February 29, 2024, while the Company undertakes a search to identify the Company’s next permanent Chief Financial Officer, Treasurer and principal financial officer.”
Sean Cassidy departed as Chief Financial Officer, Treasurer and principal financial officer at ARVINAS, INC..
“On February 15, 2024, Sean Cassidy indicated that he would step down as Chief Financial Officer, Treasurer and principal financial officer of Arvinas, Inc., a Delaware corporation (the “Company”), effective February 29, 2024, to pursue another professional opportunity.”
ARVINAS, INC. entered into Registration Rights Agreement with the Investors valued at Company agreed to register for resale the Shares and Pre-Funded Warrant Shares (effective 2023-11-24).
“Also on November 24, 2023, the Company entered into a registration rights agreement (the " Registration Rights Agreement ") with the Investors, pursuant to which the Company agreed to register for resale the Shares and the shares of the Company’s common stock issuable upon exercise of the Pre-Funded Warrants (the " Pre-Funded Warrant Shares " and, together with the Shares, the " Registrable Securities ").”
ARVINAS, INC. entered into Securities Purchase Agreement with EcoR1 Capital, LLC and other institutional accredited investors valued at aggregate gross proceeds of approximately $350 million (effective 2023-11-24).
“On November 24, 2023, Arvinas, Inc., a Delaware corporation (the " Company "), entered into a securities purchase agreement (the " Securities Purchase Agreement ") with certain institutional accredited investors (the " Investors "), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 12,963,542 shares of the Company’s common stock, par value $0.001 per share (the " Shares "), at a price of $21.36 per share, and, to one Investor in lieu of Shares, pre-funded warrants to purchase 3,422,380 shares of the Company’s common stock (the " Pre-Funded Warrants "), at a price of $21.359 per Pre-Funded Warrant (the " Private Placement ").”
ARVINAS, INC. reported financial results for the third quarter ended September 30, 2023.
“On November 7, 2023 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a corporate update.”
ARVINAS, INC. reported financial results for the quarter ended June 30, 2023.
“On August 8, 2023, Arvinas, Inc. announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.”
ARVINAS, INC.: Amended and restated bylaws effective June 15, 2023, including amendments to stockholder meeting procedures and director provisions (effective 2023-06-15).
“On June 15, 2023, the board of directors (the “Board”) of Arvinas, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.”
ARVINAS, INC. shareholders approved Ratification of Deloitte & Touche LLP as independent auditor at the 2023-06-15 meeting.
“3. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified. For: 45,089,248 Against: 49,688 Abstain: 9,222”
ARVINAS, INC. shareholders approved Non-binding advisory vote on executive compensation at the 2023-06-15 meeting.
“2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved. For: 34,800,219 Against: 6,836,514 Abstain: 14,236 Broker Non-Votes: 3,497,189”
ARVINAS, INC. shareholders approved Election of Class II Directors at the 2023-06-15 meeting.
“1. The following nominees were elected to the Board as Class II directors for terms expiring at the 2026 annual meeting of stockholders. For Withheld Broker Non-Votes Sunil Agarwal, M.D. 41,514,134 136,835 3,497,189 Leslie V. Norwalk Esq. 31,416,802 10,234,167 3,497,189 John Young 41,528,221 122,748 3,497,189”
ARVINAS, INC. reported financial results for first quarter ended March 31, 2023.
“announced its financial results for the quarter ended March 31, 2023”
David Loomis was appointed as Principal Accounting Officer at ARVINAS, INC..
“On December 15, 2022, the Board appointed David Loomis, Vice President and Chief Accounting Officer of the Company, age 49, as principal accounting officer of the Company in lieu of Sean Cassidy, Chief Financial Officer and Treasurer of the Company.”
Everett Cunningham was appointed as Director at ARVINAS, INC..
“On and effective December 15, 2022, upon recommendation from the Nominating and Corporate Governance Committee of the Board, the Board elected Everett Cunningham, age 55, as a director of the Company, effective immediately upon the resignation of Mr. Margus.”
Bradley Margus resigned as Director at ARVINAS, INC..
“On December 14, 2022, Bradley Margus notified Arvinas, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”) and the Audit Committee of the Board, effective December 15, 2022.”
ARVINAS, INC. reported financial results for quarter ended September 30, 2022.
“On November 8, 2022 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2022.”
John Young was elected as Director at ARVINAS, INC..
“On August 18, 2022, the Board elected John Young as a director of the Company, effective immediately.”
Liam Ratcliffe resigned as Director at ARVINAS, INC..
“On August 16, 2022, Liam Ratcliffe notified Arvinas, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective August 16, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.